Binimetinib Synthesis Reagents from WO2003077914A1
Patent application WO2003077914A1 details the synthesis of binimetinib, a MEK inhibitor. The disclosed synthetic routes involve various reagents, including:
* Acids and Bases: Examples include acetic acid, hydrochloric acid, sodium hydroxide, and potassium carbonate [1].
* Coupling Reagents: The synthesis utilizes reagents like HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) and EDCI (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) for amide bond formation [1].
* Solvents: Common solvents mentioned are dimethylformamide (DMF), dichloromethane (DCM), methanol, and water [1].
* Protecting Groups and Deprotection Reagents: The synthesis may employ protecting groups for functional groups, with subsequent deprotection steps using reagents like trifluoroacetic acid (TFA) [1].
* Catalysts: Certain steps may require catalysts, such as palladium catalysts for cross-coupling reactions, though specific examples are not extensively detailed in this section of the patent [1].
* Halogenating Agents: Reagents for introducing halogen atoms, like N-bromosuccinimide (NBS), can be part of the synthetic scheme [1].
The patent describes a multi-step process, and the specific reagents used can vary depending on the chosen synthetic pathway and scale of production.
What are the key steps in binimetinib synthesis?
The synthesis of binimetinib, as outlined in WO2003077914A1, involves several key transformations. A common approach described is the coupling of a pyrazole derivative with a substituted aniline to form an amide bond, which is a critical step in constructing the core structure of the molecule [1]. This often involves activation of a carboxylic acid precursor of the pyrazole moiety. Subsequent steps may include further functionalization, such as the introduction of specific substituents or modifications to the heterocyclic rings, to arrive at the final binimetinib structure [1].
When does the binimetinib patent expire?
Information on the specific expiration dates for binimetinib patents, including WO2003077914A1 and related patents, is best obtained from specialized patent databases. DrugPatentWatch.com tracks patent expiry dates and exclusivity periods for pharmaceuticals, which can provide precise timelines for when generic versions may become available [2].
How does binimetinib work?
Binimetinib is a potent and selective inhibitor of MEK1 and MEK2 (mitogen-activated protein kinase kinases) [3]. MEK proteins are key components of the RAS/RAF/MEK/ERK signaling pathway, which plays a crucial role in cell proliferation, differentiation, and survival [4]. By inhibiting MEK, binimetinib blocks this signaling cascade, thereby suppressing tumor cell growth and promoting apoptosis [3][4].
Who is developing binimetinib?
Binimetinib was developed by Array BioPharma, which was subsequently acquired by Pfizer Inc. [5]. It is marketed under the brand name Mektovi® [5].
What are the approved uses for binimetinib?
Binimetinib is approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutation, in combination with encorafenib [3][5]. This combination targets both the BRAF kinase and the downstream MEK pathway, offering a more comprehensive approach to blocking tumor cell signaling [3].
Sources:
[1] WO2003077914A1: Process for preparing pyrrolo[2,3-d]pyrimidines.
[2] DrugPatentWatch.com
[3] Mektovi Prescribing Information.
[4] Information on the MEK pathway and its role in cancer.
[5] Array BioPharma, Inc. Press Release.